AllianceBernstein’s Ovid Therapeutics OVID Stock Holding History

AllianceBernstein’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-47,780	Closed	-$14.9K	–	3302
2025 Q1	$14.9K	Hold	47,780	–	–	﹤0.01%	3185
2024 Q4	$44.6K	Sell	47,780 -100	-0.2%	-$112	﹤0.01%	3193
2024 Q3	$56.5K	Hold	47,880	–	–	﹤0.01%	3184
2024 Q2	$36.8K	Buy	+47,880	New	+$133K	﹤0.01%	3205
2021 Q2	–	Sell	-56,100	Closed	-$226K	–	3388
2021 Q1	$226K	Hold	56,100	–	–	﹤0.01%	3019
2020 Q4	$130K	Hold	56,100	–	–	﹤0.01%	3077
2020 Q3	$322K	Hold	56,100	–	–	﹤0.01%	2780
2020 Q2	$413K	Buy	+56,100	New	+$262K	﹤0.01%	2727
2018 Q4	–	Sell	-11,746	Closed	-$67K	–	3131
2018 Q3	$67K	Buy	+11,746	New	+$89K	﹤0.01%	3105

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

AllianceBernstein's OVID Position: Q2 2025 in Review

AllianceBernstein sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 47,780 shares — an estimated $14.9K sold.

AllianceBernstein first reported a position in OVID in Q3 2018 and held it in 9 quarters. The position peaked at $413K in Q2 2020. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

AllianceBernstein reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
AllianceBernstein sold 47,780 Ovid Therapeutics shares in Q2 2025, an estimated $14.9K.
AllianceBernstein first reported a position in Ovid Therapeutics in Q3 2018 and held it in 9 quarters.
AllianceBernstein's Ovid Therapeutics position peaked at $413K in Q2 2020.
71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.